Last Updated on October 17, 2024 by The Health Master
The United States Food and Drugs Administration (USFDA) has given final approval to Zydus Lifesciences to market Febuxostat tablets, 40 mg and 80 mg, according to a statement from Zydus.
Febuxostat tablets are indicated to lower hyperuricemia (high uric acid in the blood) in patients with gout who have been treated with allopurinol that did not work well or cannot be treated with allopurinol.
The drug will be manufactured at the formulation manufacturing facility of Zydus at Moraiya, Ahmedabad, the statement said.
USFDA gives approval for Prasugrel tablets
USFDA approves Fesoterodine Fumarate Extended-Release tablets
USFDA gives final approval for this Insomnia drug
USFDA approves this monoclonal antibody to treat multiple sclerosis
USFDA gives final approval to this breast cancer injection
USFDA gives approval for Fulvestrant injection
Sale of coronary stents: High Court seeks stand of Centre and NPPA
USFDA gives approval for Prasugrel tablets
IPC publishes draft monograph revision proposals
High demand for Indian generic drugs in China
Govt Job: For the post of Director at CDTL, CDSCO
List of approved FDCs (Fixed Dose Combinations) Updated
List of approved New Drugs Updated
NPPA extends ceiling price of LMO, Oxygen Inhalation
Drug licences of these two firms suspended: FDA Manipur
Latest Notifications regarding Pharmaceutical
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
